1(2018) Food & Drug Administration. Facts about the current good manufacturing practices (CGMPs).

2(2009) Food and Drug Administration, US Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluatilon and Research. Guidance for industry. Q8 (R2) pharmaceutical development.(Revision 2).

3(2008) Food and Drug Administration, US Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluatilon and Research. Content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs) additional.

4Brown SA, Levi B, Lequeux C, Wong VW, Mojallal A, Longaker MT (2010) Basic science review on adipose tissue for clinicians. Plast Reconstr Surg126: 1936-1946.

5De Francesco F, Ricci G, D'Andrea F, Nicoletti GF, Ferraro GA (2015) Human adipose stem cells: From bench to bedside. Tissue Eng Part B Rev 21: 572-584.

6Zuk PA, Zhu M, Ashjian P, et al. (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279-4295.

7Zuk PA, Zhu M, Mizuno H, et al. (2001) Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 7:211-228.

8Strem BM, Hicok KC, Zhu M, et al. (2005) Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 54:132-141.

9Clarke D (2018) Addressing particulates, extractables and leachables and the quality of single-use systems for cell and gene therapy manufacturing. Cell Gene Therapy Insights 4:187-196.